Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.50 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.44 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3293088 | 0.78 | ALDH1A1 (0.63) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL173688 | 0.76 | KDM4E (0.61) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL458846 | 0.76 | KDM4E (0.61) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3863268 | 0.76 | KDM4E (0.61) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL5137768 | 0.76 | KDM4E (0.61) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4057148 | 0.76 | KDM4E (0.61) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6249816 | 0.76 | KDM4E (0.61) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL20945207 | 0.76 | KDM4E (0.61) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL11242759 | 0.74 | KDM4E (0.58) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL11449941 | 0.73 | KDM4E (0.56) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304567-A1 | PYRROLIDIONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-10-02 | — | — | US | disclosed |
| EP-4219460-B1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA INC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC., | 2025-01-09 | — | — | US | disclosed |
| US-12152026-B2 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| WO-2024125626-A1 | NITROGENOUS COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | NUPHASE THERAPEUTICS (HANGZHOU) LIMITED., CO. (CN) | 2024-06-20 | — | — | WO | disclosed |
| CN-117917405-A | KIF18A protein inhibitors | 杭州邦顺制药有限公司 | 2024-04-23 | — | — | CN | disclosed |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| EP-4219460-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | Sitari Pharma, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230167110-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | SCHRÖDINGER, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230146125-A1 | FORMS AND COMPOSITIONS OF INHIBITORS OF JAK2 | AJAX THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| EP-3833348-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC (US) | 2021-06-16 | — | — | EP | disclosed |
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| CN-112789040-A | Transglutaminase 2(TG2) inhibitors | 思达利医药公司 | 2021-05-11 | — | — | CN | disclosed |
| WO-2020033784-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| EP-2582675-B1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | CHANGZHOU LE SUN PHARMACEUTICALS LTD (CN) | 2016-06-08 | — | — | EP | disclosed |
| CN-103068802-B | Compounds for treating proliferative disorders | LE SUN PHARMACEUTICALS LTD | 2014-12-03 | — | — | CN | disclosed |
| US-8829003-B2 | Compounds for treating proliferative disorders | CHANGZHOU LE SUN PHARMACEUTICALS LIMITED (CN) | 2014-09-09 | — | — | US | disclosed |
| US-20130190325-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | ITEK VENTURES PTY LTD (AU) | 2013-07-25 | — | — | US | disclosed |
| EP-2125811-A2 | N-(AMINO-HETEROARYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDES DERIVATIVES, PREPARATION THEREOF AND THEIR USE IN THERAPY | Sanofi-Aventis (FR) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008093024-A2 | N-(AMINO-HETEROARYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDES DERIVATIVES, PREPARATION THEREOF AND THEIR USE IN THERAPY | SANOFI-AVENTIS (FR) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304567-A1 | PYRROLIDIONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | NFKBIA, IKBKG, IKBKB | KDM4E 2721/4885GRIN2D 3551/4885GRIN3B 2247/4885 |
| US-20210163480-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | TGM2, TGM3, TGM1 | KDM4E 2034/4885GRIN2D 868/4885GRIN3B 1432/4885 |
| US-12152026-B2 | Transglutaminase 2 (TG2) inhibitors | TGM2, TGM3, TGM1 | KDM4E 2034/4885GRIN2D 868/4885GRIN3B 1432/4885 |
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | TGM2, TGM3, TGM1 | KDM4E 2034/4885GRIN2D 868/4885GRIN3B 1432/4885 |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | KDM4E 444/4885GRIN2D 4093/4885GRIN3B 2370/4885 |
| US-20230167110-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | KDM4E 444/4885GRIN2D 4093/4885GRIN3B 2370/4885 |
| US-20230146125-A1 | FORMS AND COMPOSITIONS OF INHIBITORS OF JAK2 | JAK2, JAK1, JAK3 | KDM4E 1726/4885GRIN2D 4754/4885GRIN3B 3866/4885 |
| US-20130190325-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | JAK3, CDK3, PHKA1 | KDM4E 2161/4885GRIN2D 2723/4885GRIN3B 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.